AC-PHSCN-NH2
Brain and Central Nervous System Tumors
National Institutes of Health Clinical Center (CC)protein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
48 Active assets in the Brain and Central Nervous System Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Procarbazine Universitätsmedizin Mannheim | Phase 3 | BBB |
VINCRISTINE SULFATE Northwestern University | Phase 3 | BBB |
Irinotecan EpicentRx, Inc. | Phase 2 | BBB |
ETOPOSIDE NewLink Genetics Corporation | Phase 3 | BBB |
Gefetinib Memorial Sloan Kettering Cancer Center | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
AC-PHSCN-NH2 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →